Stay updated with breaking news from Biocon Biologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eris Lifesciences has announced that it has reached a definitive agreement to acquire the dermatology and nephrology branded formulations business units of Biocon Biologics in India. The deal is valued at Rs 366 crore. The acquisition will be partially funded through debt financing.
Stocks to watch: Shares of firms like Tata Motors, SBI, Adani Wilmar, PB Fintech, IndiGo, Lupin, and others will be in focus on Thursday's trade.
USFDA: The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022 that the agency found to be adequate and indicated that it would require a re-inspection of the Malaysia facility prior to the approval of the application.
Get latest articles and stories on Latest News at LatestLY. Biotechnology major Biocon on Saturday said the US health regulator has issued a complete response letter for Biocon Biologics' application for Insulin Aspart, a proposed biosimilar for diabetes treatment. Latest News | USFDA Issues Complete Response Letter for Proposed Biosimilar Insulin Aspart: Biocon.
Bengaluru: Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced that the Company has completed the integration of the acquired biosimilars business from Viatris in North America...